1. Royal Biologics and Fair Winds Medical partnered to distribute spine and orthopedic biologics.
2. SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.
3. LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.
4. Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer.
5. Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal’s Agili-C implant in Washington state.
6. Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.
7. The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034.
8. Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
